Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Research & Development: 2009-2024

Historic Research & Development for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Dec 2024 value amounting to $12.6 million.

  • Catalyst Pharmaceuticals' Research & Development fell 19.09% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.7 million, marking a year-over-year increase of 35.83%. This contributed to the annual value of $12.6 million for FY2024, which is 86.42% down from last year.
  • Catalyst Pharmaceuticals' Research & Development amounted to $12.6 million in FY2024, which was down 86.42% from $93.2 million recorded in FY2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' Research & Development peaked at $93.2 million during FY2023, and registered a low of $12.6 million during FY2024.
  • For the 3-year period, Catalyst Pharmaceuticals' Research & Development averaged around $41.9 million, with its median value being $19.8 million (2022).
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Research & Development surged by 370.72% in 2023 and then crashed by 86.42% in 2024.
  • Yearly analysis of 5 years shows Catalyst Pharmaceuticals' Research & Development stood at $16.5 million in 2020, then grew by 2.66% to $16.9 million in 2021, then increased by 16.85% to $19.8 million in 2022, then surged by 370.72% to $93.2 million in 2023, then crashed by 86.42% to $12.6 million in 2024.